LDXHF
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.01 | $6M | $588,574 |
| 2025 Q4 | -0.00 | $6M | $2M |
| 2024 Q2 | -0.01 | $6M | -$12M |
| 2024 Q4 | -0.00 | $8M | $6M |
| 2023 Q2 | -0.01 | $3M | -$5M |
| 2023 Q4 | -0.01 | $5M | -$4M |
| 2022 Q2 | -0.03 | $5M | -$6M |
| 2022 Q4 | -0.22 | $6M | -$7M |